Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942027 | 0.90 | LMNA (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL23289890 | 0.85 | LMNA (0.39) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101413 | 0.84 | LMNA (0.33) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101358 | 0.84 | CHRM1 (0.42) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL21597936 | 0.83 | CHRM1 (0.35) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101373 | 0.82 | CHRM1 (0.40) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22472866 | 0.81 | LMNA (0.36) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101382 | 0.81 | CYP11B1 (0.34) | LMNACHRM2KMT2AMAPTPOLB | |
| SCHEMBL17101383 | 0.81 | PADI4 (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL17101520 | 0.80 | CHRM1 (0.43) | LMNACHRM2MAPTPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | claimed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | claimed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | claimed |
| EP-3119396-A1 | MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | claimed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-10428088-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | LMNA 2124/4885CHRM2 2/4885ADRA2A 28/4885 |
| US-10428088-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CHRM2 2/4885ADRA2A 28/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CHRM2 2/4885ADRA2A 28/4885 |
| US-10030035-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2124/4885CHRM2 2/4885ADRA2A 28/4885 |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | LMNA 305/4885CHRM2 16/4885ADRA2A 81/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | LMNA 305/4885CHRM2 16/4885ADRA2A 81/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | LMNA 2166/4885CHRM2 2/4885ADRA2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.